IP Verse

Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure - EP3294283

The patent EP3294283 was granted to Novartis on Mar 8, 2023. The application was originally filed on May 9, 2016 under application number EP16722388A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3294283

NOVARTIS
Application Number
EP16722388A
Filing Date
May 9, 2016
Status
Granted And Under Opposition
Feb 3, 2023
Publication Date
Mar 8, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (16)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BULLE DRDec 8, 2023KUTZENBERGER WOLFF & PARTNERADMISSIBLE
KRKADec 8, 2023HOFFMANN EITLEADMISSIBLE
ZENTIVADec 8, 2023GREINERADMISSIBLE
ALFRED E TIEFENBACHERDec 7, 2023HAMM & WITTKOPPADMISSIBLE
BETAPHARM ARZNEIMITTELDec 7, 2023HAMM & WITTKOPPADMISSIBLE
GENERICS UKDec 7, 2023ELKINGTON AND FIFEADMISSIBLE
POLPHARMADec 7, 2023HAMM & WITTKOPPADMISSIBLE
SANOVEL IIAC SAN VE TICDec 7, 2023KRAUS & LEDERERADMISSIBLE
SANOVEL IIAC SAN VE TICDec 7, 2023KRAUS & LEDERER PARTGMBBADMISSIBLE
STRAWMANDec 7, 2023PINSENT MASONSADMISSIBLE
SYNTHONDec 7, 2023HAMM & WITTKOPPADMISSIBLE
TEVA PHARMACEUTICALSDec 7, 2023D YOUNGADMISSIBLE
HOFFMANN EITLEDec 4, 2023HOFFMANN EITLEWITHDRAWN
DR SCHONNov 30, 2023DR SCHONADMISSIBLE
CAMULONNov 23, 2023REDDIE & GROSEADMISSIBLE
EGISOct 9, 2023STOLMAR & PARTNERADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0443983
DESCRIPTIONUS5217996
DESCRIPTIONUS5399578
DESCRIPTIONWO03059345
DESCRIPTIONWO2007056546
DESCRIPTIONWO2009061713
DESCRIPTIONWO2014029848
OPPOSITIONWO03059345
OPPOSITIONWO2014029848
OPPOSITIONWO2015030711
OPPOSITIONWO2016181284

Non-Patent Literature (NPL) Citations (100) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- Anonymous, "ENTRESTO PRESCRIBING INFORMATION", (20150801), URL: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf, (20160616), XP055280940 [XP] 1-61 * See section 2.1: Dosing. *
INTERNATIONAL-SEARCH-REPORT- Anonymous, "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients - Full Text View - ClinicalTrials.gov", (20130812), URL: https://clinicaltrials.gov/ct2/show/NCT01922089?term=NCT01922089&rank=1, (20160616), XP055281080 [XD] 1-61 * the whole document *
INTERNATIONAL-SEARCH-REPORT- KOBALAVA, Z; PAVLIKOVA, E; AVERKOV, O; MOISEEV, V; ALBRECHT, D; FENG, A; CHANDRA, P; JORDAAN, P J, "First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure", CIRCULATION, (20101123), vol. 122, no. 21 (supplement), ISSN 0009-7322, XP009190562 [X] 1-61 * the whole document *
INTERNATIONAL-SEARCH-REPORT- JOHN J.V. MCMURRAY ET AL, "Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure", NEW ENGLAND JOURNAL OF MEDICINE, (20140911), vol. 371, no. 11, doi:10.1056/NEJMoa1409077, ISSN 0028-4793, pages 993 - 1004, XP055175908 [X] 1-61 * the whole document *
INTERNATIONAL-SEARCH-REPORT- JOHN J. V. MCMURRAY ET AL, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", EUROPEAN JOURNAL OF HEART FAILURE, NL, (20130405), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544 [X] 1-61 * abstract * * figure 1 * * page 1064, 'LC active run-in period' * * page 1068, column 1, line 17 - column 2, line 31 *
INTERNATIONAL-SEARCH-REPORT- KAZUOMI KARIO ET AL, "LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension", THE JOURNAL OF CLINICAL HYPERTENSION, US, (20150924), vol. 18, no. 4, doi:10.1111/jch.12667, ISSN 1524-6175, pages 308 - 314, XP055280953 [XP] 1-61 * the whole document *
INTERNATIONAL-SEARCH-REPORT- GU J ET AL, "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)", JOURNAL OF CLINICAL PHARMACOLOGY, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 50, no. 4, doi:10.1177/0091270009343932, ISSN 1552-4604, (20100401), pages 401 - 414, (20091123), XP002718352 [A] 1-61 * the whole document *
OPPOSITION- Abda, "Vergleichstabelle: ACE-Hemmer", ABDA - Arzneimitte Kommission Deutschen Apotheker, (20200525), pages 1 - 3, ABDA - Arzneimitte Kommission Deutschen Apotheker, URL: https://www.abda.de/fileadmin/user_upload/assets/Arzneimittelkommission/Aequivalenzdosistabellen/ACEi_AEquivalenzdosistabelle.pdf, (20240404), XP093147891
OPPOSITION- Aktories, Klaus ; Förstermann, Ulrich ; Hofmann, Franz ; Starke, Klaus ; Forth, Wolfgang , "7.2 Beeinflussung der Kontraktionskraft des Herzens; 17.2 Beeinflussung der Kontraktionskraft des Herzens", Aktories, Klaus ; Förstermann, Ulrich ; Hofmann, Franz ; Starke, Klaus ; Forth, Wolfgang , Aktories/Förstermann/Hofmann/Starke, Allgemeine und spezielle Pharmakologie und Toxikologie, Urban & Fischer, (20050101), vol. 130, pages 421 - 434, ISBN 978-3-437-44490-6, XP009553238
OPPOSITION- Anonymous, "COMMISSION DECISION of 22.1.2009 concerning, in the framework of Article 29 of Regulation (EC) No 1901/2006 of the European Parliament and of the Council, the marketing authorisation of "Cozaar and associated names", medicinal products for human use which contain the active substance "losartan potassium"", COMMISSION OF THE EUROPEAN COMMUNITIES, (20090122), COMMISSION OF THE EUROPEAN COMMUNITIES, XP093194472
OPPOSITION- Anonymous, "DIOVAN - HIGHLIGHTS OF PRESCRIBING INFORMATION ", (20140901), (20240404), XP093148134
OPPOSITION- Anonymous, "Diovan (Valsartan) Tablets. FDA label. Reference ID: 3199353", Novartis Pharmaceuticals Corp., (20121001), pages 1 - 20, XP055780468
OPPOSITION- Anonymous, "Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)", ClinicalTrials.gov; NCT01920711, (20130812), ClinicalTrials.gov; NCT01920711, URL: https://classic.clinicaltrials.gov/ct2/show/NCT01920711, (20240405), XP093148484
OPPOSITION- Anonymous, "ENTRESTO PRESCRIBING INFORMATION", (20150801), URL: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf, (20160616), XP055280940
OPPOSITION- Anonymous, "Entresto - Summary of Product Characteristics", (20151119), (20240404), XP093148148
OPPOSITION- Anonymous , "Herzinsuffizienz", Anonymous , Mutschler, Geisslinger, Kroemer, Menzel, Ruth, Mutschler - Arzneimittelwirkungen, Stuttgart , Wissenschaftliche Verlagsgesellschaft , (20130101), pages 510,541 - 545, ISBN 978-3-8047-2898-1, XP093148934
OPPOSITION- Anonymous, "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction", ClinicalTrials.gov; NCT00887588, (20130814), ClinicalTrials.gov; NCT00887588, URL: https://clinicaltrials.gov/study/NCT00887588?tab=histoiy&a=12, (20240326), XP093145907
OPPOSITION- Anonymous, "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction", ClinicalTrials.gov, U.S. National Library of Medicine, Internet, Internet, (20090424), pages 1 - 12, ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/record/NCT00887588, (20211124), XP055865148
OPPOSITION- Anonymous, "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction - History of Changes for Study: NCT00887588", ClinicalTrials.gov; NCT00887588, (20140625), ClinicalTrials.gov; NCT00887588, URL: https://classic.clinicaltrials.gov/ct2/history/NCT00887588?A=12&B=12&C=merged#StudyPageTop, XP093172721
OPPOSITION- Anonymous, "New heart failure agent safe and tolerated in clinical practice ", Pace-cme, (20150526), pages 1 - 2, Pace-cme, URL: https://pace-cme.org/2015/05/25/new-haert-fallure-agent-safe-and-tolerated-in-clinical-practice/, (20240408), XP093148728
OPPOSITION- Anonymous, " Novartis' heart failure medicine LCZ696 granted FDA priority review", Novartis, (20150213), XP093148356
OPPOSITION- Anonymous, "PRAC assessment report - For renin-angiotensin system (RAS)-acting agents Procedure number: EMEA/H/A-31/1370", European Medicines Agency (EMA); EMA/PRAC/294920/2014 Pharmacovigilance Risk Assessment Committee (PRAC), (20140522), European Medicines Agency (EMA); EMA/PRAC/294920/2014 Pharmacovigilance Risk Assessment Committee (PRAC), (20240322), XP093144500
OPPOSITION- Anonymous, "Restriction of combined use of medicines affecting the renin-angiotensin system (RAS) ", European Medicines Agency; EMA/554928/2014, (20140909), European Medicines Agency; EMA/554928/2014, URL: https://www.ema.europa.eu/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents, (20240405), XP093148362
OPPOSITION- Anonymous, "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients - Full Text View - ClinicalTrials.gov", URL: https://clinicaltrials.gov/ct2/show/NCT01922089?term=NCT01922089&rank=1, (20160616), XP055281080
OPPOSITION- Anonymous, "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (TITRATION)", ClinicalTrials.gov ID NCT01922089, (20151015), ClinicalTrials.gov ID NCT01922089, URL: https://classic.clinicaltrials.gov/ct2/show/NCT01922089, (20240404), XP093147861
OPPOSITION- Anonymous, "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (TITRATION)", ClinicalTrials.gov; NCT01922089, (20090101), ClinicalTrials.gov; NCT01922089, URL: https://www.clinicaltrials.gov/study/NCT01922089, (20240326), XP093145909
OPPOSITION- Anonymous, "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (TITRATION) - History of Changes for Study: NCT01922089", (20150916), pages 1 - 28, ClinicalTrials.gov; NCT01922089, (20240322), XP093144505
OPPOSITION- Anonymous, "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (TITRATION) - History of Changes for Study: NCT01922089", ClinicalTrials.gov; NCT01922089, (20140924), ClinicalTrials.gov; NCT01922089, URL: https://classic.clinicaltrials.gov/ct2/history/NCT01922089?A=6&B=6&C=merged#StudyPageTop, XP093170340
OPPOSITION- Anonymous, "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (TITRATION) - History of Changes for Study: NCT01922089", ClinicalTrials.gov; NCT01922089, (20150916), ClinicalTrials.gov; NCT01922089, (20240322), XP093144505
OPPOSITION- Anonymous, "Therapie der Herzinsuffizienz", Mutschler Arzneimittelwirkungen Pharmakologie - Klinische Pharmakologie - Toxikologie, (20200101), pages 435 - 435, ISBN 978-3-8047-3663-4, XP093148941
OPPOSITION- Anonymous, "TITRATION study confirms LCZ696 safe and tolerated in clinical practice", European Society of Cadiology, (20150523), European Society of Cadiology, URL: https://www.escardio.org/The-ESC/Press-Office/Press-releases/TITRATION-study-confirms-LCZ696-safe-and-tolerated-in-clinical-practice, (20240405), XP093148477
OPPOSITION- Anonymous, "VASOTEC tablets", (20141201), (20240404), XP093148142
OPPOSITION- Basile Jan N., "Titration of beta-blockers in heart failure. How to maximize benefit while minimizing adverse events", Postgraduate Medicine, (20030301), vol. 113, no. 3, pages 63 - 70, XP055980347
OPPOSITION- Chen Fabian, Alan Charney , Jim Gong , Victor Shi , Michele Senni, "086 Comparison of the Baseline Demographics of the LCZ696 PARADIGM-HF and TITRATION Studies", Clinical Trials, (20150801), pages S45 - S45, XP093148447
OPPOSITION- Colledge, Nicki R. ; Walker, Brian R. ; Ralston, Stuart H. ; Davidson, Sir Stanley, "2 - Good prescribing - Practical prescribing", Colledge, Nicki R. ; Walker, Brian R. ; Ralston, Stuart H. ; Davidson, Sir Stanley, Nicholas A. Boon, Nicki R. Colledge, Brian R. Walker, John A.A. Hunter, DAVIDSON'S PRINCIPLE & PRACTICE OF MEDICINE (20th Edition), Churchill Livingstone Elsevier, (20060101), pages 17 - 35, ISBN 978-0-443-10057-4, XP009555067
OPPOSITION- D75 - ES003_CR1 - Prof. Iain Squire Declaration
OPPOSITION- D76 - ES003_CR2 - BNF Entresto guidelines
OPPOSITION- Davila Carine, Elisabeth Askin, "02. ACE Inhibitor Conversion Table", Outpatient Handbook, (20230101), Outpatient Handbook, URL: https://hospitalhandbook.ucsf.edu/02-ace-inhibitor-conversion-table/02-ace-inhibitor-conversion-table, (20240404), XP093147873
OPPOSITION- Delagarza Vincent W, "Pharmacologic Treatment of Alzheimer's Disease: An Update", American family physician, (20031001), vol. 68, no. 7, ISSN 0002-838x, pages 1365 - 1372, XP008091098
OPPOSITION- Jackowski Leslie, Roshmeen Azam, "Beta blockers in systolic heart failure", Australian family physician, Mosby, (20080301), vol. 37, no. 3, pages 137 - 139, XP093148766
OPPOSITION- Kao-Chang Lin, Hsi-Ming Chen, Wei-Hung Chen, Wei-Ta Chen, Yen-Yu Chen, Jong-Ling Fuh, Sung-Tsang Hsieh, Li-Chi Hsu, Kai-Dih Juang, Ryh-Huei Lin, Chung-Hsiang Liu, Shiang-Ru Lu, Jing-Jane Tsai, Po-Jen Wang, Shuu-Jiun Wang, Zin-An Wu, "Treatment Guidelines for preventive treatment of migraine", Acta neurologica Taiwanica, (20080101), vol. 17, no. 2, ISSN 1019-6099, pages 132 - 148, XP009553248
OPPOSITION- Kobalava Zhanna, Pavlikova Elena, Averkov Oleg, Moiseev Valentin, Albrecht Diego, Feng Aimen, Chandra Priyamvada, Jordaan Pierre J, "Abstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure", Circulation, (20180323), vol. 122, no. Suppl. 21, XP093147856
OPPOSITION- Kobalava Zhanna, Pavlikova Elena, Averkov Oleg, Moiseev Valentin, Albrecht Diego, Feng Aimen, Chandra Priyamvada, Jordaan Pierre J, "bstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure", Circulation, (20180323), vol. 122, no. Suppl. 21, page A19378, XP093147856
OPPOSITION- Kobalava Zhanna, Pavlikova Elena, Averkov Oleg, Moiseev Valentin, Albrecht Diego, Feng Aimen, Chandra Priyamvada, Jordaan Pierre J, "bstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure", Circulation, (20180323), vol. 122, no. Suppl. 21, XP093147856
OPPOSITION- Kobalava Zhanna; Pavlikova Elena; Averkov Oleg; Moiseev Valentin; Albrecht Diego; Feng Aimen; Chandra Priyamvada; Jordaan Pierre J, "First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure", Circulation, American Heart Association, US, US , (20101101), vol. 122, no. 21, Suppl., ISSN 0009-7322, XP009190562
OPPOSITION- Koch D., "Vergleichstabelle Angiotensin II -Rezeptor Antagonisten (Sartane)", Kantonsspital Aarau, (20200115), Kantonsspital Aarau, URL: https://www.ksa.ch/sites/default/files/cms/spitalpharmazie/docs/sartane_vergleichstabelle-spitalpharmazie-ksa.pdf, (20240404), XP093147896
OPPOSITION- Lang Chim C, Struthers Allan D., "Targeting the renin-angiotensin-aldosterone system in heart failure", Nature Reviews Cardiology, (20130301), vol. 10, pages 125 - 134, XP055788520
OPPOSITION- McMurray, J. Cohen-Solal, A. Dietz, R. Eichhorn, E. Erhardt, L. Hobbs, F.D.R. Krum, H. Maggioni, A. McKelvie, R.S. Pina, I.L. Soler-Soler, J. Swedberg, K., "Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20050801), vol. 7, no. 5, ISSN 1388-9842, pages 710 - 721, XP005011092
OPPOSITION- McMurray, J. ; Cohen-Solal, A. ; Dietz, R. ; Eichhorn, E. ; Erhardt, L. ; Hobbs, F.D.R. ; Krum, H. ; Maggioni, A. ; McKelvie, R.S. ; Pina, I.L. ; Soler-Soler, J. ; Swedberg, K., "Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20050801), vol. 7, no. 5, ISSN 1388-9842, pages 710 - 721, XP027706770
OPPOSITION- Rph Angevine, "THE DOSE. An estimation of equivalent doses between ARBs andACEIs", Thames Valley Family Health Team Drug Resource, (20200101), Thames Valley Family Health Team Drug Resource, URL: https://thamesvalleyfht.ca/wp-content/uploads/2020/05/TheDoseACEIsARBs-drina.pdf, (20240404), XP093147884
OPPOSITION- Shammas F V, K. Dickstein, "Clinical Pharmacokinetics in Heart Failure", Shammas F V, K. Dickstein, Amitabh Prakash , Anton van Rensburg, Clinical Pharmacokinetics, Adis Press Limited, (19880801), pages 94 - 113, XP093148776
OPPOSITION- Valsartan, "Prescribing information for Diovan", VALSARTAN, (20120101), pages 1 - 20, XP093093489
OPPOSITION- Voors Adriaan A., Gori Mauro, Liu Licette C.Y., Claggett Brian, Zile Michael R., Pieske Burkert, Mcmurray John J.V., Packer Milton, Shi Victor, Lefkowitz Martin P., Solomon Scott D., "in patients with heart failure and preserved ejection fraction", European journal of heart failure, NL , (20150501), vol. 17, no. 5, doi:10.1002/ejhf.232, ISSN 1388-9842, pages 510 - 517, XP093148787
OPPOSITION- Ferrari Roberto, Böhm Michael, Cleland John G.F., Paulus Walter J.S., Pieske Burkert, Rapezzi Claudio, Tavazzi Luigi, "Heart failure with preserved ejection fraction: uncertainties and dilemmas", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20150701), vol. 17, no. 7, doi:10.1002/ejhf.304, ISSN 1388-9842, pages 665 - 671, XP093194467
OPPOSITION- Senni Michele, Mcmurray John J.V., Wachter Rolf, Mcintyre Hugh F., Reyes Antonio, Majercak Ivan, Andreka Peter, Shehova‐yankova Nina, Anand Inder, Yilmaz Mehmet B., Gogia Harinder, Martinez‐selles Manuel, Fischer Steffen, Zilahi Zsolt, Cosmi Franco, Gelev Valeri, Galve Enrique, Gómez‐doblas Juanjo J., Nociar Jan, Radomska Maria, Sokolova Beata, Volterrani Maurizio, Sarkar Arnab, Reimund Bernard, Chen Fabian, Charney Alan, "Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20160901), vol. 18, no. 9, doi:10.1002/ejhf.548, ISSN 1388-9842, pages 1193 - 1202, XP093147870
OPPOSITION- U. C. Hoppe, E. Erdmann, "Passage; 5.6 Medikamentöse Therapie der chronischen systolischen Herzinsuffizienz", U. C. Hoppe, E. Erdmann, Erland Erdmann, Klinische Kardiologie Krankheiten des Herzens, des Kreislaufs und der herznahen GefaBe, Berlin, Springer, (20110611), pages 150 - 161, doi:10.1007/978-3-642-16481-1_5, ISBN 978-3-642-16480-4, XP093148944
OPPOSITION- Frank P. Brouwers; Hans L. Hillege; Wiek H. van Gilst; Dirk J. van Veldhuisen, "Comparing New Onset Heart Failure with Reduced Ejection Fraction and New Onset Heart Failure with Preserved Ejection Fraction: An Epidemiologic Perspective", Current Heart Failure Reports, Current Science Inc., New York, New York , (20120912), vol. 9, no. 4, doi:10.1007/s11897-012-0115-7, ISSN 1546-9549, pages 363 - 368, XP035134729
OPPOSITION- Borer Jeffrey S, Komajda Michel, Ford Ian, Tavazzi Luigi, Dominjon Fabienne, Maya Juan, Wu Yuna, Depre Christophe, Böhm Michael, "085 Effects of Heart Rate Reduction in Black Patients from the SHIFT (Systolic Heart Failure treatment with the If Inhibitor Ivabradine Trial) Study - Clinical Trials I ", The 19th Annual Scientific Meeting, (20150801), vol. 21, no. 8, doi:10.1016/j.cardfail.2015.06.156, XP093148481
OPPOSITION- O'meara Eileen, Thibodeau-Jarry Nicolas, Ducharme Anique, Rouleau Jean Lucien, "The Epidemic of Heart Failure: A Lucid Approach to Stemming the Rising Tide", Canadian journal of cardiology, PULSUS GROUP, INC., CANADA, CANADA , (20141201), vol. 30, no. 12, doi:10.1016/j.cjca.2014.09.032, ISSN 0828-282X, pages S442 - S454, XP093194468
OPPOSITION- L. FENG et al., "LCZ696: a dual-acting sodium supramolecular complex", Tetrahe- dron Letters, (20120000), vol. 53, doi:10.1016/j.tetlet.2011.11.029, pages 275 - 276, XP028393477
OPPOSITION- Lili Feng; Piotr H. Karpinski; Paul Sutton; Yugang Liu; David F. Hook; Bin Hu; Thomas J. Blacklock; Philip E. Fanwick; Mahavir Prashad; Sven Godtfredsen; Christoph Ziltener;, "LCZ696: a dual-acting sodium supramolecular complex", Tetrahedron Letters, Elsevier, Amsterdam , NL, Amsterdam , NL , (20111105), vol. 53, no. 3, doi:10.1016/j.tetlet.2011.11.029, ISSN 0040-4039, pages 275 - 276, XP028393477
OPPOSITION- RUILOPE et al., "Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", Lancet, (20100410), vol. 375, no. 9722, doi:10.1016/S0140-6736(09)61966-8, pages 1255 - 66, XP027490781
OPPOSITION- Ruilope, L.M. ; Dukat, A. ; Bohm, M. ; Lacourciere, Y. ; Gong, J. ; Lefkowitz, M.P., "Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100410), vol. 375, no. 9722, doi:10.1016/S0140-6736(09)61966-8, ISSN 0140-6736, pages 1255 - 1266, XP027490781
OPPOSITION- Scott D Solomon, Michael Zile, Burkert Pieske, Adriaan Voors, Amil Shah, Elisabeth Kraigher-Krainer, Victor Shi, Toni Bransford, Madoka Takeuchi, Jianjian Gong, Martin Lefkowitz, Milton Packer, John Jv Mcmurray, "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", The Lancet, ¬J.B. Flint|, (20121001), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61227-6, ISSN 01406736, pages 1387 - 1395, XP055083562
OPPOSITION- SOLOMON et al., "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with reserved ejection fraction: a phase 2 double-blind randomised controlled trial", Lancet, (20121020), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61227-6, pages 1387 - 95, XP055083562
OPPOSITION- SOLOMON, SCOTT D et al., "The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial", The Lancet., (20120826), vol. 380, no. 9851, doi:10.1016/S0140-6736(12)61227-6, pages 1387 - 1395, XP055083562
OPPOSITION- Just H, "Medikamentöse Therapie bei Herzinsuffizienz", Therapeutische umschau, CH , (20000501), vol. 57, no. 5, doi:10.1024/0040-5930.57.5.313, ISSN 0040-5930, pages 313 - 320, XP093148807
OPPOSITION- I. SADAYOSHI et al., "Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction", Hypertension Research, (20150000), vol. 38, doi:10.1038/hr.2015.1, pages 269 - 275, XP093148349
OPPOSITION- Ito Sadayoshi, Satoh Minoru, Tamaki Yuko, Gotou Hiromi, Charney Alan, Okino Naoko, Akahori Mizuki, Zhang Jack, "Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction", HYPERTENSION RESEARCH. CLINICAL AND EXPERIMENTAL., OSAKA., JP, JP , (20150401), vol. 38, no. 4, doi:10.1038/hr.2015.1, ISSN 0916-9636, pages 269 - 275, XP093148349
OPPOSITION- Lim Gregory B., "LCZ696—a PARADIGM shift in treatment for heart failure", Nature Reviews Cardiology, Nature Publishing Group, GB, GB , (20141101), vol. 11, no. 11, doi:10.1038/nrcardio.2014.139, ISSN 1759-5002, pages 618 - 618, XP093144488
OPPOSITION- COHN J N, TOGNONI G, "A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20011206), vol. 345, no. 23, doi:10.1056/NEJMoa010713, ISSN 1533-4406, pages 1667 - 1675, XP009033568
OPPOSITION- COHN J N, TOGNONI G, "A RANDOMIZED TRIAL OF THE ANGIOTENSIN-RECEPTOR BLOCKER VALSARTAN IN CHRONIC HEART FAILURE", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20011206), vol. 345, no. 23, doi:10.1056/NEJMoa010713, ISSN 1533-4406, pages 1667 - 1675, XP009033568
OPPOSITION- Theophilus E Owan, M D, Hodge David O, M S, Herges Regina M, B S, Jacobsen Steven J, M D, Ph D, Roger Veronique L, M D, M P H, Redfield Margaret M, M D, Background, " Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction", The new england journal of medicine, (20060101), vol. 355, doi:10.1056/NEJMoa052256, pages 251 - 259, XP055393398
OPPOSITION- J. J. V. MCMURRAY et al., "Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure", N Engl J Med, (20140000), vol. 371, doi:10.1056/NEJMoa1409077, pages 993 - 1004, XP055175908
OPPOSITION- John J.V. Mcmurray, Milton Packer, Akshay S. Desai, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure", New England Journal of Medicine, New England Journal of Medicine, (20140911), vol. 371, no. 11, doi:10.1056/NEJMoa1409077, ISSN 00284793, pages 993 - 1004, XP055175908
OPPOSITION- Dickstein K., Cohen-Solal A., Filippatos G., Mcmurray J. J.V., Ponikowski P., Poole-Wilson P. A., Stromberg A., Van Veldhuisen D. J., Atar D., Hoes A. W., Keren A., Mebazaa A., Nieminen M., Priori S. G., Swedberg K., Vahanian A., Camm J., De Caterina R., Dean V., Funck-Brentano C., Hellemans I., Kristensen S. D., Mcgregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J. L., Auricchio A., Bax J., Bohm M., Corra U., Della Bella P., Elliott P. M., Follath F., Gheorghiade M., Hasin Y., Hernborg A., Jaarsma T., Komajda M., Kornowski R., Piepoli M., Prendergast B., Tavazzi L., Vachiery J.-L., Verheugt F. W. A., Zannad F., "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)", European Heart Journal, Oxford University Press, GB, GB , (20081001), vol. 29, no. 19, doi:10.1093/eurheartj/ehn309, ISSN 0195-668X, pages 2388 - 2442, XP093145908
OPPOSITION- Piotr Ponikowski, Adriaan A. Voors, Stefan D. Anker, Héctor Bueno, John G. F. Cleland, Andrew J. S. Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A. Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T. Parissis, Burkert Pieske, Jillian P. Riley, Giuseppe M. C. Rosano, Luis M. Ruilope, Frank Ruschitzka, Frans H. Rutten, Peter Van Der Meer, "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure", European Heart Journal, Oxford University Press, GB, GB , (20160714), vol. 37, no. 27, doi:10.1093/eurheartj/ehw128, ISSN 0195-668X, pages 2129 - 2200, XP055360432
OPPOSITION- Düngen Hans-Dirk, Apostolović Svetlana, Inkrot Simone, Tahirović Elvis, Töpper Agnieszka, Mehrhof Felix, Prettin Christiane, Putniković Biljana, Nešković Aleksandar N., Krotin Mirjana, Sakač Dejan, Lainščak Mitja, Edelmann Frank, Wachter Rolf, Rau Thomas, Eschenhagen Thomas, Doehner Wolfram, Anker Stefan D., Waagstein Finn, Herrmann-Lingen Christoph, Gelbrich Goetz, Dietz Rainer, "Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20110601), vol. 13, no. 6, doi:10.1093/eurjhf/hfr020, ISSN 1388-9842, pages 670 - 680, XP093145904
OPPOSITION- John J. V. Mcmurray, Milton Packer, Akshay S. Desai, Jim Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", European journal of haert failure, NL , (20130901), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544
OPPOSITION- John J. V. Mcmurray, Milton Packer, Akshay S. Desai, Jim Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact", EUROPEAN JOURNAL OF HEART FAILURE, ELSEVIER, AMSTERDAM, NL, NL , (20130901), vol. 15, no. 9, doi:10.1093/eurjhf/hft052, ISSN 1388-9842, pages 1062 - 1073, XP055161544
OPPOSITION- Steckler Anne E, Bishu Kalkidan, Wassif Heba, Sigurdsson Gardar, Wagner Judy, Jaenicke Connie, Vats Shashank, Rector Thomas, Anand Inder S, "Telephone Titration of Heart Failure Medications", JOURNAL OF CARDIOVASCULAR NURSING, ASPEN PUBLISHERS, FREDERICK, MD, US, US , (20110101), vol. 26, no. 1, doi:10.1097/JCN.0b013e3181ec1223, ISSN 0889-4655, pages 29 - 36, XP009556418
OPPOSITION- Pergolizzi Joseph, Böger Rainer H, Budd Keith, Dahan Albert, Erdine Serdar, Hans Guy, Kress Hans‐georg, Langford Richard, Likar Rudolf, Raffa Robert B., Sacerdote Paola, "Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone)", Pain practice, US , (20080701), vol. 8, no. 4, doi:10.1111/j.1533-2500.2008.00204.x, ISSN 1530-7085, pages 287 - 313, XP093148817
OPPOSITION- J. Nielsen; P. Damkier; H. Lublin; D. Taylor, "Optimizing clozapine treatment", ACTA psychiatrica scandinavica, DE , (20110428), vol. 123, no. 6, doi:10.1111/j.1600-0447.2011.01710.x, ISSN 0001-690X, pages 411 - 422, XP071044011
OPPOSITION- Kazuomi Kario, Yuko Tamaki, Naoko Okino, Hiromi Gotou, Min Zhu, Jack Zhang, "LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension", The journal of clinical hypertension, Le Jacq Communications, US, US , (20160401), vol. 18, no. 4, doi:10.1111/jch.12667, ISSN 1524-6175, pages 308 - 314, XP055280953
OPPOSITION- Yancy Clyde W., Jessup Mariell, Bozkurt Biykem, Butler Javed, Casey Donald E., Colvin Monica M., Drazner Mark H., Filippatos Gerasimos, Fonarow Gregg C., Givertz Michael M., Hollenberg Steven M., Lindenfeld Joann, Masoudi Frederick A., Mcbride Patrick E., Peterson Pamela N., Stevenson Lynne Warner, Westlake Cheryl, "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America", Circulation, American Heart Association, US, US , (20160927), vol. 134, no. 13, doi:10.1161/CIR.0000000000000435, ISSN 0009-7322, XP093194466
OPPOSITION- Yancy Clyde W., Jessup Mariell, Bozkurt Biykem, Butler Javed, Casey Donald E., Drazner Mark H., Fonarow Gregg C., Geraci Stephen A., Horwich Tamara, Januzzi James L., Johnson Maryl R., Kasper Edward K., Levy Wayne C., Masoudi Frederick A., Mcbride Patrick E., Mcmurray John J.V., Mitchell Judith E., Peterson Pamela N., Riegel Barbara, Sam Flora, Stevenson Lynne W., Tang W.H. Wilson, Tsai Emily J., Wilkoff Bruce L., "2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines", Circulation, American Heart Association, US, US , (20131015), vol. 128, no. 16, doi:10.1161/CIR.0b013e31829e8776, ISSN 0009-7322, pages e240 - e327, XP055889103
OPPOSITION- Bozkurt Biykem, "Response to Ryan and Parwani: Heart Failure Patients With Low Blood Pressure: How Should We Manage Neurohormonal Blocking Drugs?", Circulation. Heart Failure, US , (20121101), vol. 5, no. 6, doi:10.1161/CIRCHEARTFAILURE.112.972240, ISSN 1941-3289, pages 820 - 821, XP093148781
OPPOSITION- GOTTLIEB et al., "Tolerability of beta-Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF", Circulation, (20020312), vol. 105, no. 10, doi:10.1161/hc1002.105180, pages 1182 - 8, XP093148346
OPPOSITION- GU et al., "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi", J. Clin. Pharmacol., (20100400), vol. 50, no. 4, doi:10.1177/0091270009343932, pages 401 - 14, XP002718352
OPPOSITION- Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel D F, Jeng A Y, Lin T H, Zheng W, Dole W P, "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).", Journal of clinical pharmacology, Wiley-Blackwell Publishing, Inc., US, US , (20100401), vol. 50, no. 4, doi:10.1177/0091270009343932, ISSN 1552-4604, pages 401 - 414, XP002718352
OPPOSITION- Cada Dennis J., Baker Danial E., Leonard James, "Sacubitril/Valsartan - Formulary Drug Reviews", HOSPITAL PHARMACY., LIPPINCOTT, PHILADELPHIA., US, US , (20151201), vol. 50, no. 11, doi:10.1310/hpj5011-1025, ISSN 0018-5787, pages 1025 - 1036, XP093148348
OPPOSITION- Ripley Toni L, "Valsartan in Chronic Heart Failure", ANNALS OF PHARMACOTHERAPY, Harvey Whitney Books Company, US, US , (20050301), vol. 39, no. 3, doi:10.1345/aph.1E327, ISSN 1060-0280, pages 460 - 469, XP093148962
OPPOSITION- Minguet Joan, Sutton Gemma, Ferrero Carmen, Gomez Timothy, Bramlage Peter, "LCZ696: a new paradigm for the treatment of heart failure?", Expert Opin Pharmacother, Ashley Publications LTD, London, UK, London, UK , (20150211), vol. 16, no. 3, doi:10.1517/14656566.2015.1000300, ISSN 1465-6566, pages 435 - 446, XP093148128
OPPOSITION- Zaccara Gaetano, Tramacere Luciana, Cincotta Massimo, "Drug safety evaluation of zonisamide for the treatment of epilepsy", Expert opinion on drug safety, GB , (20110701), vol. 10, no. 4, doi:10.1517/14740338.2011.571201, ISSN 1474-0338, pages 623 - 631, XP093148825
OPPOSITION- Mohammed Asim A, Ianuzzi James L, "Natriuretic Peptide Guided Heart Failure Management", Current Clinical Pharmacology, Bentham Science Publishers Ltd., NL, NL , (20090101), vol. 4, no. 2, doi:10.2174/157488409788184945, ISSN 1574-8847, pages 87 - 94, XP093148953
OPPOSITION- Krum Henry, Andrea Driscoll , "Management of heart failure", The medical journal of Australia, (20130902), vol. 199, no. 5, doi:10.5694/mjal2.10993, pages 334 - 339, XP093148794
OTHER- Anonymous, "Diovan (Valsartan) Tablets. FDA label. Reference ID: 3199353", Novartis Pharmaceuticals Corp., (20121001), pages 1 - 20, XP055780468
OTHER- McMurray, J. ; Cohen-Solal, A. ; Dietz, R. ; Eichhorn, E. ; Erhardt, L. ; Hobbs, F.D.R. ; Krum, H. ; Maggioni, A. ; McKelvie, R.S. ; Pina, I.L. ; Soler-Soler, J. ; Swedberg, K., "Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice", EUROPEAN JOURNAL OF HEART FAILURE, NL , (20050801), vol. 7, no. 5, ISSN 1388-9842, pages 710 - 721, XP027706770
OTHER- COHN J N, TOGNONI G, "A RANDOMIZED TRIAL OF THE ANGIOTENSIN-RECEPTOR BLOCKER VALSARTAN IN CHRONIC HEART FAILURE", New England Journal of Medicine, US , (20011206), vol. 345, no. 23, doi:10.1056/NEJMoa010713, ISSN 1533-4406, pages 1667 - 1675, XP009033568
OTHER- John J.V. Mcmurray, Milton Packer, Akshay S. Desai, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor C. Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, "Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure", New England Journal of Medicine, (20140911), vol. 371, no. 11, doi:10.1056/NEJMoa1409077, ISSN 00284793, pages 993 - 1004, XP055175908

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents